RIQAS Pre-eclampsia EQA Prorgamme

RIQAS Pre-eclampsia EQA Prorgamme

In Vitro Diagnostic Tests

Information

Ensure Accuracy in Preeclampsia Testing with Our New EQA Programme. This programme is designed to support laboratories in ensuring the reliability of biomarker testing for preeclampsia, helping to improve patient care and outcomes. Join the many laboratories worldwide committed to excellence in diagnostics. - Comprehensive yet easy to interpret results - Human based serum ensuring a commutable sample matrix - Frequent reporting allows early identification of system errors - Lyophilised samples for user convenience - The largest international EQA scheme ensures a large peer group and therefore meaningful comparisons - Report turnaround time of less than 72-hours, reducing costly errors with patient samples Contact us to learn more: Qualitycontrol@randox.com
Randox Laboratories LtdZ4.B10Randox is committed to improving health worldwide with the firm belief that the healthcare of tomorrow depends on innovations developed today. Our passion for innovation, creativity and investment in R&D enables us to continually develop our products and evolve for the future. As a world leader in the in-vitro diagnostics industry, Randox is committed to developing revolutionary diagnostic products designed to improve health globally including chemistry, immunoassay, molecular & POC analysers in addition to high quality reagents. Leading provider of complete quality control solutions including; daily quality control, calibration verification and proficiency testing for results you can trust. Biochip Array Technology is a unique multiplexing method offering clinical, research and molecular panels. We also offer a range of COVID-19 testing solutions for all testing needs. Randox is leading the change in moving from a one-size-fits-all approach towards decisions and products tailored to the needs of the individual.

Join the event!